Publication: Subcutaneous portacath utilization in pediatric oncology patients: Ramathibodi hospital experience
Issued Date
1999-12-01
Resource Type
ISSN
01252208
Other identifier(s)
2-s2.0-28144455520
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Journal of the Medical Association of Thailand. Vol.82, No.SUPPL. (1999)
Suggested Citation
Wanpen Panthangkool, Suapsan Singhapakdi, Sumate Teeraratkul, Sani Molagool, Samart Pakakasama, Phongjan Hathirat, Suradej Hongeng Subcutaneous portacath utilization in pediatric oncology patients: Ramathibodi hospital experience. Journal of the Medical Association of Thailand. Vol.82, No.SUPPL. (1999). Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/25521
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Subcutaneous portacath utilization in pediatric oncology patients: Ramathibodi hospital experience
Other Contributor(s)
Abstract
Subcutaneous portacaths (SQP) placement in 19 pediatric oncology patients were studied. Complications of SQP were evaluated. Two patients had premature SQP removal due to fungal infection and breakage, 1 for each. Two patients had catheter-related bacteremia which was resolved by antibiotic administration. Only 1 patient had occasional difficult blood drawing episodes, because the tip of catheter was inserted through external jugular vein instead of subclavian vein. There were no other serious complications except that some of them had clotted formations, which were resolved easily by urokinase administration. Long-term SQP utilization was possible in 17 of 19 patients, with the average time of 7.5 months. Few complications occurred in the group of patients studied. SQP improved quality of medical care and significantly lessened the anxiety of patients who need long-term chemotherapy treatment. Therefore, placement of the intravenous access device is feasible for pediatric oncology patients in Thailand. The patients are no longer suffering from repeated venipunctures. Although it is expensive, it is convenient and useful for some patients with relatively high socioeconomic status. It should be considered for every pediatric cancer patient who needs prolonged chemotherapy and who has affordable means.